Clinical Trials Logo
  1. Home
  2. Erdheim-Chester Disease
  3. NCT06332183

GWAS and EWAS in Patients With Erdheim-Chester Disease

Erdheim-Chester Disease Clinical Trial

Official title:
Genome-wide Association Study (GWAS) and Epigenome-wide Association Study (EWAS) in Patients With Erdheim-Chester Disease

Clinical Trial Summary

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the condition are still unknown, and although some mutations in genes involved in cell proliferation have been identified, other factors may be involved. Susceptibility to developing rare diseases like ECD is typically associated with genetic factors, including DNA polymorphisms and epigenetic modifications. This study aims to analyze the entire genome of a large cohort of patients with ECD and healthy controls to determine whether there are polymorphisms and epigenetic variants associated with susceptibility to developing the disease. The study could thus clarify the genetic predisposition to ECD development, provide insights into disease pathogenic mechanisms, and identify proteins or cellular mechanisms potentially targeted by specific treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06332183
Study type Observational
Source Meyer Children's Hospital IRCCS
Contact Augusto Vaglio
Phone 3200026532
Email augusto.vaglio@meyer.it
Status Recruiting
Phase
Start date July 17, 2019
Completion date October 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06317246 - Subtypes and Prognostic Factors in Erdheim-Chester Disease N/A
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Recruiting NCT03329274 - Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Recruiting NCT05093335 - In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET Early Phase 1
Completed NCT02608619 - Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Terminated NCT01727206 - Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Phase 2
Recruiting NCT02089724 - Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease N/A
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT05768178 - DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Phase 2/Phase 3
Terminated NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Withdrawn NCT03794297 - Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Phase 2
Active, not recruiting NCT05092815 - The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation Phase 2
Recruiting NCT04079179 - Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Phase 2